Tidal Investments LLC Buys 61,165 Shares of The Cooper Companies, Inc. $COO

Tidal Investments LLC raised its stake in The Cooper Companies, Inc. (NASDAQ:COO) by 281.4% during the 2nd quarter, Holdings Channel.com reports. The firm owned 82,903 shares of the medical device company’s stock after buying an additional 61,165 shares during the quarter. Tidal Investments LLC’s holdings in Cooper Companies were worth $5,945,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in COO. California State Teachers Retirement System lifted its position in shares of Cooper Companies by 6,101.7% during the second quarter. California State Teachers Retirement System now owns 19,460,014 shares of the medical device company’s stock valued at $1,395,478,000 after buying an additional 19,146,230 shares during the last quarter. BlackRock Inc. purchased a new position in shares of Cooper Companies in the 2nd quarter worth approximately $1,077,762,000. State Street Corp raised its stake in shares of Cooper Companies by 2.4% during the 4th quarter. State Street Corp now owns 8,793,747 shares of the medical device company’s stock worth $720,736,000 after acquiring an additional 207,195 shares in the last quarter. Wellington Management Group LLP raised its stake in shares of Cooper Companies by 332.9% during the 3rd quarter. Wellington Management Group LLP now owns 6,184,992 shares of the medical device company’s stock worth $424,043,000 after acquiring an additional 4,756,178 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its position in Cooper Companies by 58.8% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 6,028,821 shares of the medical device company’s stock valued at $494,123,000 after acquiring an additional 2,231,568 shares during the last quarter. 24.39% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on COO shares. The Goldman Sachs Group set a $61.00 target price on shares of Cooper Companies in a research note on Wednesday, May 27th. Wells Fargo & Company set a $61.00 price target on Cooper Companies and gave the stock an “equal weight” rating in a research report on Thursday. Citigroup reiterated a “neutral” rating and set a $60.00 price objective (down from $80.00) on shares of Cooper Companies in a report on Thursday. Weiss Ratings reissued a “sell (d)” rating on shares of Cooper Companies in a research report on Friday, September 4th. Finally, Robert W. Baird set a $61.00 target price on Cooper Companies and gave the stock a “neutral” rating in a research note on Thursday. Five research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $71.47.

Key Headlines Impacting Cooper Companies

Here are the key news stories impacting Cooper Companies this week:

• Positive Sentiment: Cooper reported adjusted fiscal Q3 earnings of $1.15 per share, ahead of the approximately $1.11–$1.12 consensus, with earnings up from $0.49 a year earlier. Cost controls and continued fertility-related growth helped offset weakness elsewhere. Cooper Companies Bets on Fertility Growth Despite Weakness in CooperVision
• Positive Sentiment: The board authorized an additional $1 billion of repurchases, bringing the total buyback authorization to $3 billion. The program could support per-share earnings and signal management believes COO shares are undervalued. Cooper Outlines Q4 EPS and Adds to Buyback Authorization
• Neutral Sentiment: Cooper completed a strategic review but chose not to pursue a sale or separate transaction for CooperSurgical. Keeping the business preserves its fertility-growth opportunity, but investors had apparently anticipated a potential deal or value-unlocking action. Cooper Cos. Stock Drops After Soft Outlook and No Deal
• Negative Sentiment: Revenue rose only about 1% to $1.066 billion, missing the roughly $1.10 billion consensus. U.S. channel destocking and inventory reductions pressured CooperVision, raising concerns about near-term demand and sales momentum. COO Q3 Earnings Top Estimates, Revenues Miss on Destocking
• Negative Sentiment: Management reduced fiscal 2026 earnings guidance to $4.51–$4.55 per share and issued fourth-quarter guidance of $1.05–$1.09, below prior expectations. The weaker outlook triggered multiple analyst downgrades and price-target cuts, including from Baird, UBS, JPMorgan and William Blair.
• Negative Sentiment: Law firms have announced securities-fraud investigations connected with the post-earnings decline. These notices are often promotional, but they add to negative investor sentiment and potential legal uncertainty. Securities Fraud Investigation Into Cooper Companies Announced

Cooper Companies Stock Performance

Cooper Companies stock opened at $53.91 on Monday. The stock has a 50-day moving average price of $71.62 and a 200 day moving average price of $69.61. The company has a market capitalization of $10.25 billion, a price-to-earnings ratio of 18.40, a price-to-earnings-growth ratio of 2.19 and a beta of 0.82. The Cooper Companies, Inc. has a 52 week low of $51.01 and a 52 week high of $89.83. The company has a quick ratio of 0.73, a current ratio of 1.22 and a debt-to-equity ratio of 0.23.

Cooper Companies (NASDAQ:COO) last posted its quarterly earnings results on Wednesday, September 9th. The medical device company reported $1.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.12 by $0.03. Cooper Companies had a net margin of 13.46% and a return on equity of 10.90%. The company had revenue of $1.07 billion during the quarter, compared to analyst estimates of $1.10 billion. During the same period last year, the firm posted $0.49 EPS. Cooper Companies’s revenue for the quarter was up .5% compared to the same quarter last year. Cooper Companies has set its Q4 2026 guidance at 1.050-1.090 EPS and its FY 2026 guidance at 4.510-4.550 EPS. Sell-side analysts anticipate that The Cooper Companies, Inc. will post 4.53 EPS for the current year.

Cooper Companies declared that its board has initiated a share repurchase plan on Wednesday, September 9th that allows the company to buyback $3.00 billion in shares. This buyback authorization allows the medical device company to repurchase up to 22.7% of its stock through open market purchases. Stock buyback plans are typically a sign that the company’s board of directors believes its stock is undervalued.

Cooper Companies Profile

Cooper Companies, Inc is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company develops, manufactures and markets products through two primary business segments: CooperVision and CooperSurgical.

CooperVision specializes in contact lenses, including daily disposable, toric, multifocal, multifocal toric, specialty and myopia-management lenses. Its products are designed to address a range of vision-correction needs, including astigmatism, presbyopia and irregular corneas.